The guidelines for myeloma treatment are changing to allow earlier treatment, even without some of the typical symptoms or disease damage. The goal is to treat earlier and prevent severe damage that myeloma causes. Learn more about these new guidelines from Dr. Vincent Rajkumar, MD of the Mayo Clinic on this very important show.

When patients harvest stem cells in preparation for autologous transplant, can they be "cleaned up" or can all residual myeloma cells be completely removed before they are given back during transplant? Learn how Dr. Eric Bartee, MD, PhD of the Medical University of South Carolina is using a virus to do just that.

Dr. Irene Ghobrial, MD, PhD of the Dana Farber Cancer Institute joins us to explain her recent discovery of a compound that can prevent myeloma from spreading into the bone, protecting patients from one of the most damaging effects of the blood cancer. Join us to learn more about this very exciting discovery.

Join us as we talk with renown myeloma expert Dr. Jesus San Miguel of the University Hospital of Salamanca about high risk myeloma, recent findings of the International Myeloma Working Group and his work on minimal residual disease.

Learn from Dr. Larry Kwak, MD, PhD about the latest in immunotherapy; specifically for vaccine use in myeloma. Dr. Kwak was noted on the 2010 Time list of Most Influential People for his vaccine work in lymphoma. As Professor and Chair of the Department of Lymphoma and Myeloma at the University of Texas M.D. Anderson Cancer center, he has 20+ years of experience in cancer vaccines and will share how his success in lymphoma is being advanced in myeloma.

Join us as we talk with Dr. Sarah Holstein, MD, PhD of the Roswell Park Cancer Institute about her work to outsmart myeloma resistance and her work to target the bone marrow microenvironment via a variety of pathways.

Join us as we talk with Dr. Jay Bradner, MD of the Bradner Lab, Dana Farber Cancer Institute and Harvard Medical School. Dr. Bradner focuses his research on the use of chemical biology to target gene regulatory pathways. Specifically, Dr. Bradner is working to develop a MYC inhibitor for myeloma. MYC is the most common translocation to be found in multiple myeloma and increases in prevalance as the disease progresses, so finding a target for this translocations is critical. 

Join us as we talk with Dr. Jay Bradner, MD of the Bradner Lab, Dana Farber Cancer Institute and Harvard Medical School. Dr. Bradner focuses his research on the use of chemical biology to target gene regulatory pathways. Specifically, Dr. Bradner is working to develop a MYC inhibitor for myeloma. MYC is the most common translocation to be found in multiple myeloma and increases in prevalance as the disease progresses, so finding a target for this translocations is critical.

Do all multiple myeloma patients need continuous maintenance therapy? Join us as we talk with Dr. Antonio Palumbo, MD on HealthTree Podcast for Multiple Myeloma about the recent data to suggest that this may be the case.

Join us as we learn more about the new Hevylite® test for myeloma patients - when it should be used and why it is important with Dr. Stephen Harding of The Binding Site.